Supporting the use of a coagulometric method for rivaroxaban control: A hypothesis-generating study to define the safety cut-offs

Thrombosis Journal

Volumn 13, Issue 1, 2015, Pages

  Altman, Raul ^a   Gonzalez, Claudio Daniel ^b  

^a Centro de Trombosis de Buenos Aires   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Anticoagulants; Drug monitoring; Reference ranges; Rivaroxaban; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; RIVAROXABAN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING TEST; BLOOD SAMPLING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HEMOSTASIS; HEMOSTASIS TESTING SYSTEM; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESENTERIC VEIN THROMBOSIS; MORNING DOSAGE; PORTAL VEIN THROMBOSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SENSITIVITY ANALYSIS; THROMBOEMBOLISM;

EID: 84938577607     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-015-0058-9     Document Type: Article

References (24)

1. Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thrombos Haemost. 2013;11:390-4.
2. Bosworth HB, Bradi B, Granger BB, Mendys P, Brindis R, Burkholder R, et al. Medication adherence: a call for action. Am Heart J. 2011;162:412-24.
3. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39:632-6.
4. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013;11:11.
5. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756-60.
6. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128-39.
7. Altman R, Gonzalez CD. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb J. 2014;12:7.
8. Exner T, Ellwood L, Rubie J, Barancewicz A. Testing for new oral anticoagulants with LA resistant russells viper venom reagents. an in vitro study. Thromb Haemost. 2013;109:762-5.
9. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379-87.
10. Dargaud Y, Hoffman M, Lefrapper L, Lin F-C, Genty A, Chatard B, et al. Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. J Thromb Haemost. 2013;11:1043-52.
11. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35:407-15.
12. Brown DL, Kouides PA. Diagnosis and treatment of inherited factor X deficiency. Haemophilia. 2008;14:1176-82.
13. Shim YJ, Won DI. Pharmacokinetics and prophylactic use of FEIBA® in a child with severe congenital factor X deficiency and recurrent spontaneous intracranial haemorrhage: a case report. Haemophilia. 2013;19:e364-7.
14. Rauch R, Girisch M, Wiegand G, Schroeder W, Hofbeck M, Welisch E, et al. Factor X deficiency and intracranial bleeding: who is at risk? Haemophilia. 2011;17:759-63.
15. Furuhata M1, Doki N, Hishima T, Okamoto T, Koyama T, Kaito S. Acquired factor X deficiency associated with atypical AL-amyloidosis. Intern Med. 2014;53:1841-5.
16. Enjeti AK, Walsh M, Seldon M. Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis. Haemophilia. 2005;11:535-8.
17. Brummel-Ziedins KE, Orfeo T, Gissel M, Mann KG, Rosendaal FR. Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation. PLoS One. 2012;7, e29178.
18. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11:10.
19. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. Einstein-DVT dose-ranging study investigators. a dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the einstein-DVT dose-ranging study. Blood. 2008;112:2242-7.
20. Douros A, Schlemm L, Bolbrinker J, Ebinger M, Kreutz R. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. Thromb Haemost. 2014;112:419-20.
21. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med. 2014. doi: 10.1515/cclm-2014-0767 .
22. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37:1056-64.
23. ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013;11:8.
24. Beyer-Westendorf J, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124:955-62.